CEACAM6 induces epithelial-mesenchymal transition and mediates invasion and metastasis in pancreatic cancer

International Journal of Oncology

Volumn 43, Issue 3, 2013, Pages 877-885

  Chen, Jianmin ^a   Li, Qiang ^a   An, Yong ^a   Lv, Nan ^a   Xue, Xiaofeng ^b   Wei, Jishu ^a   Jiang, Kuirong ^a   Wu, Junli ^a   Gao, Wentao ^a   Qian, Zhuyin ^a   Dai, Cuncai ^a   Xu, Zekuan ^a   Miao, Yi ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

CEACAM6; Epithelial mesenchymal transition; MiR 29a b c; Pancreatic cancer

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; MICRORNA 29A; MICRORNA 29B; SHORT HAIRPIN RNA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ANTIGENS, CD; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GPI-LINKED PROTEINS; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; RNA, SMALL INTERFERING;

EID: 84880609688     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2015     Document Type: Article

References (36)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet 378: 607-620, 2011.
3. Hidalgo M: Pancreatic cancer. N Engl J Med 362: 1605-1617, 2010.
4. Savagner P: The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol 21 (Suppl 7): vii89-92, 2010.
5. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
6. Iwatsuki M, Mimori K, Yokobori T, et al: Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 101: 293-299, 2010.
7. Zeisberg M and Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119: 1429-1437, 2009.
8. Rhim AD, Mirek ET, Aiello NM, et al: EMT and dissemination precede pancreatic tumor formation. Cell 148: 349-361, 2012.
9. Cano CE, Motoo Y and Iovanna JL: Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma. ScientificWorldJournal 10: 1947-1957, 2010.
10. Krantz SB, Shields MA, Dangi-Garimella S, Munshi HG and Bentrem DJ: Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res 173: 105-112, 2012.
11. Kim T, Veronese A, Pichiorri F, et al: p53 regulates epithelial- mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 208: 875-883, 2011.
12. Park SM, Gaur AB, Lengyel E and Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22: 894-907, 2008.
13. Tellez CS, Juri DE, Do K, et al: EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res 71: 3087-3097, 2011.
14. Li Y, Van den Boom TG II, Kong D, Wang Z, Ali S, Philip PA and Sarkar FH: Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69: 6704-6712, 2009.
15. Jantscheff P, Terracciano L, Lowy A, et al: Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol 21: 3638-3646, 2003.
16. Maraqa L, Cummings M, Peter MB, et al: Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen. Clin Cancer Res 14: 405-411, 2008.
17. Poola I, Shokrani B, Bhatnagar R, DeWitty RL, Yue Q and Bonney G: Expression of carcinoembryonic antigen cell adhesion molecule 6 oncoprotein in atypical ductal hyperplastic tissues is associated with the development of invasive breast cancer. Clin Cancer Res 12: 4773-4783, 2006.
18. Singer BB, Scheffrahn I, Kammerer R, Suttorp N, Ergun S and Slevogt H: Deregulation of the CEACAM expression pattern causes undifferentiated cell growth in human lung adenocarcinoma cells. PLoS One 5: e8747, 2010.
19. Ieta K, Tanaka F, Utsunomiya T, Kuwano H and Mori M: CEACAM6 gene expression in intrahepatic cholangiocarcinoma. Br J Cancer 95: 532-540, 2006.
20. Strickland LA, Ross J, Williams S, et al: Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J Pathol 218: 380-390, 2009.
21. Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene 23: 465-473, 2004.
22. Iacobuzio-Donahue CA, Maitra A, Olsen M, et al: Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 162: 1151-1162, 2003.
23. Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW and Whang EE: A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res 64: 3987-3993, 2004.
24. Fu X, Tao L, Li M, Fisher WE and Zhang X: Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. Clin Cancer Res 12: 3152-3157, 2006.
25. Duxbury MS, Matros E, Clancy T, et al: CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions. Ann Surg 241: 491-496, 2005.
26. Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW and Whang EE: Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness. Oncogene 23: 5834-5842, 2004.
27. Duxbury MS, Ito H, Benoit E, Ashley SW and Whang EE: CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness. Br J Cancer 91: 1384-1390, 2004.
28. Lewis-Wambi JS, Cunliffe HE, Kim HR, Willis AL and Jordan VC: Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells. Eur J Cancer 44: 1770-1779, 2008.
29. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 119: 1438-1449, 2009.
30. Eastham AM, Spencer H, Soncin F, Ritson S, Merry CL, Stern PL and Ward CM: Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res 67: 11254-11262, 2007.
31. Leshem O, Madar S, Kogan-Sakin I, et al: TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One 6: e21650, 2011.
32. Cummins JM, He Y, Leary RJ, et al: The colorectal microRNAome. Proc Natl Acad Sci USA 103: 3687-3692, 2006.
33. Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006.
34. Mott JL, Kobayashi S, Bronk SF and Gores GJ: mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 26: 6133-6140, 2007.
35. Braconi C, Kogure T, Valeri N, et al: microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 30: 4750-4756, 2011.
36. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH and Zhuang SM: Effects of microRNA-29 on apoptosis, tumorigenicity and prognosis of hepatocellular carcinoma. Hepatology 51: 836-845, 2010.